Scios News

In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was likely sustainable for at least the next 15 years.

If current projections for dividend growth rate remained at 8.2% per year and those for net income growth rate at ~6% per year, it was shown to be inevitable that the dividend payout ratio would continue to increase.

Ethicon Endo-Surgery , a Johnson & Johnson company, announced that the FDA granted PMA approval for its SEDASYS device, the first computer-assisted personalized sedation system for use by clinicians in the endoscopy suites.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! A former Johnson & Johnson employee has claimed in a lawsuit that she was fired because of her age and medical disability, and wrongly accused of fraud in maintaining company records.

In the lawsuit filed against a division of the New Brunswick-based company, Sylvia Santos alleges that her termination in 2012 was the result of age and disability discrimination, according to a complaint filed Thursday in Superior Court [ News Source ]

Mr. Chung holds over 20 years of extensive experience in all aspects of trademark and copyright counseling, enforcement, strategy and portfolio management, having held senior counsel positions at several dynamic multinational global corporations and having worked in private practice.

In the past few weeks, three of the top brands in the world have had to launch public apologies tied to misplaced or misguided creative, execution and strategy.

Following a Los Angeles jury's award of $8.3 million to plaintiff Loren Kransky in a DePuy ASR lawsuit, manufacturer Johnson & Johnson has asked the Los Angeles Superior Court to put the award on hold while it files an appeal, according to court documents.

These are exciting times for Johnson & Johnson with FDA product approvals setting the stage for higher growth.

The share price of Johnson & Johnson has appreciated by 32% over the past 12 months and just made its 52-week high at $85.74. In my opinion, investors should refrain from buying the shares at this level given the frothy valuations.

Several Johnson & Johnson shareholders took the health care giant to task during its annual meeting Thursday, criticizing management for repeated product recalls, ethical lapses and excessive executive pay.

Covered in fake blood and bandages, two PETA members wearing pig costumes while hobbling on crutches will join others to protest outside Johnson & Johnson's annual meeting in New Brunswick on Thursday.

The idea of a happy and meaningful life has become unnecessarily complicated in some circles, says author and certified positive psychology coach Lynda Wallace, who left a high-powered executive career with Johnson & Johnson to pursue her real passion helping individuals and groups achieve greater happiness and success.